Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats.
We investigated the effect of KIOM-79, 80% ethanolic extract of a new herbal prescription, on non-obese type 2 diabetic Goto-Kakizaki (GK) rats. The rats were treated orally with KIOM-79 (500 mg/kg body weight) once a day for 13 weeks to examine the long-term effects on hyperglycemia and glomerular histology as well as biochemical and functional abnormalities in kidney. As the results, we found that KIOM-79 reduced hyperglycemia (p<0.01), ameliorated insulin resistance (p<0.001), urinary protein excretion (p<0.01) and creatinine clearance (Ccr) (p<0.001), and inhibited glomerular AGE formation (p<0.001) in diabetic GK rats. We also found that KIOM-79 prevented the glomeruli enlargement, overexpression of type IV collagen (p<0.001), PKC protein (p<0.01), TGF-beta mRNA (p<0.05) and VEGF mRNA (p<0.05). Thus, based on our finding, KIOM-79 could reduce the hyperglycemia, and prevent or retard the development of diabetic nephropathy.
Kim
Chan-Sik
CS
Department of Herbal Pharmaceutical Development, Korea Institute of Oriental Medicine, 461-24 Jeonmin-dong, Yuseong-gu, Daejeon 305-811, Republic of Korea.
Sohn
Eun Jin
EJ
Kim
Young Sook
YS
Jung
Dong Ho
DH
Jang
Dae Sik
DS
Lee
Yun Mi
YM
Kim
Dong-Hee
DH
Kim
Jin Sook
JS
D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D024141:Collagen Type IV / Q000378:metabolism; D003401:Creatine / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism; D004334:Drug Administration Schedule; D005215:Fasting; D017127:Glycation End Products, Advanced / Q000378:metabolism; D029001:Herbal Medicine; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D007150:Immunohistochemistry; D007328:Insulin / Q000097:blood / Q000378:metabolism; D007333:Insulin Resistance; D007672:Kidney Cortex / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010936:Plant Extracts / Q000494:pharmacology*; D011493:Protein Kinase C / Q000378:metabolism; D011507:Proteinuria / Q000517:prevention & control; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D016212:Transforming Growth Factor beta / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D001786:Blood Glucose; D024141:Collagen Type IV; D017127:Glycation End Products, Advanced; D007004:Hypoglycemic Agents; D007328:Insulin; C517978:KIOM 79; D010936:Plant Extracts; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; D042461:Vascular Endothelial Growth Factor A; D011493:Protein Kinase C; D003401:Creatine